-
Siltuximab: Exploring IL-6 Inhibition in Castleman’s Disease and Research(Post)
Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the m
Distributors(Page) Validación de kit ELISA: qué medir para confiar en los datos(Post)Validación de kit ELISA: qué medir para confiar en los datos Validar un kit ELISA significa demostrar, en la matriz y condiciones reales de trabajo, que cumple criterios de precisión, linealidad, sen
Hydroxychloroquine: Potential Treatment for COVID-19(Post)Hydroxychloroquine: Potential Treatment for COVID-19 What is Hydroxychloroquine? Hydroxychloroquine (HCQ
एलिसा प्लेट धोने की युक्तियाँ(Page) What is the difference between PBS and dPBS?(Post)Lab Buffers · ProtocolsPBS vs DPBS: What’s the Difference?PBS and DPBS are the everyday isotonic, pH-balanced salt solutions used to wash, dilute and transport cells and proteins. This guide bre
Harnessing CD40 for Potent Anti-Tumor Immune Responses(Post)CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily, plays a pivotal role in regulating immune responses, particularly in activating antigen-presenting cells (APCs) an
Vopratelimab: Unlocking the Potential of ICOS in Cancer Research(Post)What You Need to Know About VopratelimabWhat is Vopratelimab?Vopratelimab is an experimental monoclonal antibody that targets the Inducible T-cell CO-Stimulator (ICOS) protein, playing a
Atezolizumab: Unveiling the Role of Anti-PD-L1 in Cancer Research(Post)Quick Facts About AtezolizumabWhat is Atezolizumab?Atezolizumab is an anti-PD-L1 monoclonal antibody used in immunotherapy to treat various cancers by enhancing the immune system's abili
Murlentamab: Revolutionizing Cancer Research with Targeted Therapy(Post)Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst
Avizakimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther
Tinurilimab: Advancing Immunotherapy Through CD47 Blockade(Post)Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Tin
Volagidemab: A Breakthrough in GLP-1 Receptor Agonists for Metabolic Disorders(Post)Quick Facts About VolagidemabWhat is Volagidemab?Volagidemab is a glucagon-like peptide-1 (GLP-1) receptor antagonist designed to regulate glucose metabolism and energy homeostasis.How D
Ulviprubart: A Breakthrough in Autoimmune Disease Treatment(Post)Quick Facts About UlviprubartWhat is Ulviprubart?Ulviprubart is an experimental complement inhibitor designed to modulate immune responses in autoimmune diseases.What is the mechanism of
CRISPR-Cas Screening for Cell Viability(Post)Key Points Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a method of gene editing that uses t
Iscalimab: Advancing Research in Autoimmune Diseases and Transplantation(Post)What You Need to Know About IscalimabWhat is Iscalimab?Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key protein involved in immune system regulation.What is the mechanis
Belimumab: Unveiling Its Role in Lupus and Beyond(Post)Quick Facts About BelimumabWhat is Belimumab?Belimumab is a monoclonal antibody used to treat systemic lupus erythematosus (SLE), an autoimmune disease. It is marketed under the brand na
Unveiling Prezalumab: Targeting the Role of Anti-CD47 in Cancer Immunotherapy(Post)What You Need to Know About PrezalumabWhat is Prezalumab?Prezalumab is a monoclonal antibody designed to target CD47, a protein often overexpressed in cancer cells to evade immune detect
細胞溶解用超音波処理プロトコル(Page)細胞溶解のための超音波処理プロトコル | Assay Genie | Assay Genie
Trauma Immunology(Post)Traumatic injuries & death When I ask people what the leading cause of death is in the United States in people age 44 and under, they generally reply saying